Uterine myomas revisited

Duhan, Nirmala; Sirohiwal, Daya

doi:10.1016/j.ejogrb.2010.05.010

Cited by 36 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies also suggest that estrogen is the major factor contributing to the development of UL. On the basis of these findings, we hypothesize that polymorphisms of the genes involved in estrogen metabolism underlie the varying sensitivity to UL in human populations [10]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Multicenter Case-Control Study on Screening of Single Nucleotide Polymorphisms in Estrogen-Metabolizing Enzymes and Susceptibility to Uterine Leiomyoma in Han Chinese

Shen¹,

Ren²,

Xu³

et al. 2014

Gynecol Obstet Invest

View full text Add to dashboard Cite

Uterine leiomyoma (UL) is an estrogen-responsive benign tumor in the female reproductive system and the main risk of hysterectomy for women. However, gene polymorphism of estrogen-metabolizing enzymes may lead to the different susceptibility to UL. We detected 10 single mucleotide polymorphisms in three key estrogen metabolite enzymes (COMT, CYP1A1, CYP1B1) in a Chinese Han population consisting of 800 patients and 800 healthy women from five different medical centers. The genetic polymorphism of rs3087869 (IVS1+2329C>T) (OR 3.200, 95% CI 1.614-6.345) and rs4680 (Val158Met) (OR 5.675, 95% CI 2.696-11.942) loci on COMT, rs1048943 (Ile462Val) (OR 4.629, 95% CI 2.216-9.672) and rs4646422 (Gly45Asp) (OR 3.240, 95% CI 1.624-6.461) loci on CYP1A1 and rs1065827 (Ala119Ser) (OR 5.635, 95% CI 2.990-10.619) locus on CYP1B1 were the risk factors to UL development and rs1056836 (Leu432Val) (OR 0.188, 95% CI 0.061-0.575) locus on CYB1B1 may be the protective factor to UL. The results provide a theoretical basis for genetic screening and early intervention to UL-susceptible populations.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It is one of the main reasons for women to undergo hysterectomy every year. However, the pathogenic mechanisms of UL remain unclear [1]. The risk factors of the development of UL should therefore be determined which could help in preventing UL [2].…”

Section: Introductionmentioning

confidence: 99%

A Multicenter Case-Control Study on Screening of Single Nucleotide Polymorphisms in Estrogen-Metabolizing Enzymes and Susceptibility to Uterine Leiomyoma in Han Chinese

Shen¹,

Ren²,

Xu³

et al. 2014

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…1 They may be asymptomatic and can generally be managed expectantly, but they are often the cause of abnormal uterine bleeding, pelvic pain, miscarriage, and infertility. 2 The management of symptomatic myomas involves various medical treatments as well as conservative or radical surgical interventions.…”

Section: Introductionmentioning

confidence: 99%

Transient Occlusion of Uterine Arteries with Endoscopic Vascular Clip Preceding Laparoscopic Myomectomy

Kwon

Jung

Lee

et al. 2013

Journal of Laparoendoscopic & Advanced Surgical Techniques

View full text Add to dashboard Cite

show abstract

“…Uterine fibroids mainly originate from individual smooth muscle cells of the uterus [3]. The smooth muscle cells of the uterine blood vessels may also be a source [4]. Although benign, fibroids may have a major impact on the quality of life of almost 50% of the women who are symptomatic.…”

Section: Introductionmentioning

confidence: 99%

Medical Management of Uterine Fibroids

Parsanezhad

Jahromi

2012

Curr Obstet Gynecol Rep

View full text Add to dashboard Cite

Uterine leiomyomas are the most common benign tumors of the uterus. Though benign, they can affect the quality of life for many women. Compared with the standard surgical treatments, medical therapy is attractive and avoids possible surgery-related complications. No medical therapy currently exists that can induce rapid regression of the myoma and symptoms with minimal side effects without affecting fertility. This review evaluates medical treatments that are currently available for the treatment of uterine fibroids.

show abstract

Uterine myomas revisited

Cited by 36 publications

References 27 publications

A Multicenter Case-Control Study on Screening of Single Nucleotide Polymorphisms in Estrogen-Metabolizing Enzymes and Susceptibility to Uterine Leiomyoma in Han Chinese

A Multicenter Case-Control Study on Screening of Single Nucleotide Polymorphisms in Estrogen-Metabolizing Enzymes and Susceptibility to Uterine Leiomyoma in Han Chinese

Transient Occlusion of Uterine Arteries with Endoscopic Vascular Clip Preceding Laparoscopic Myomectomy

Medical Management of Uterine Fibroids

Contact Info

Product

Resources

About